ND & CT rules recognize the consideration of surrogate endpoints for approval of new drugs in certain situation where, the approval of a new drug may be based on the clinical data generated considering surrogate end-point rather than using
standard outcome measures such as survival or disease progression which are reasonably likely to predict clinical benefit, or a clinical end point.
8. Surrogate ...
Accredited Consultants Pvt Ltd 2023-10-25T05:12:59 2023-10-25T05:12:59
Accredited Consultants Pvt Ltd
ND & CT rules recognize the consideration of surrogate endpoints for approval of new drugs in certai